Climb Bio to present budoprutug Phase 1b/2a 250mg data at EHA June 2026
Climb Bio will showcase safety, B-cell depletion, and initial platelet data from its 250mg budoprutug cohort at the June 13 EHA 2026 Congress following 24 weeks of treatment. The presentation covers Phase 1b/2a results in previously treated primary immune thrombocytopenia patients, informing budoprutug’s clinical profile.
1. EHA Presentation Details
Climb Bio will present budoprutug data at the European Hematology Association 2026 Congress in Stockholm from June 11-14. Poster PS2440 is scheduled for June 13, 18:45-19:45 CEST in Poster Session 2.
2. Phase 1b/2a Cohort Results
The company will report safety, B-cell depletion, and initial platelet data from the 250mg low-dose cohort after 24 weeks in previously treated primary immune thrombocytopenia patients.
3. Development and Next Steps
These preliminary findings inform budoprutug’s clinical profile for primary immune thrombocytopenia and support further evaluation of its anti-CD19 monoclonal antibody in ongoing and planned trials.